CRISPRMED25 Speakers and panelists (early confirmation)

Scientific Conference (virtual, April 7, 2025 | in-person, April 8-11, 2025)

Keynote Speaker: Virginijus Šikšnys, Prof., Ph.D., Head of Department, Vilnius University, Lithuania

Patient Advocate: Jimi Olaghere is a CASGEVY recipient who has developed a keen interest in the advancements of cell and gene therapies, since his transformative participation in the groundbreaking clinical trial. Jimi is passionate about the positive impact that these therapies can have on patients in need and has become a staunch advocate for increased accessibility of gene therapies for sickle cell disease patients worldwide. At CRISPRMED25, Jimi will share his story about living with sickle cell disease, before and after treatment with the recently approved CRISPR therapy CASGEVY.

• Alessia Cavazza, Ass. Prof., Group Leader, Infection, Immunity & Inflammation Department at University College London's Great Ormond Street Institute of Child Health, England
• Alessio Strano, Ph.D., Postdoctoral scientist in the Platt Laboratory for Biological Engineering of ETH Zürich, Switzerland.
• Alvin Luk, Co-Founder, CEO, and Head of Medical at HuidaGene Therapeutics, Inc., United States
• Anna Cereseto, Prof., Vice-Director, Centre for Integrative Biology (CIBIO), University of Trento, Italy
• Annarita Miccio, Group Leader, Ph.D., Imagine Institute of Genetic Diseases, France
• Attila Sebe, MD, Ph.D., Paul-Ehrlich-Institute, Federal Institute for Vaccines and Biomedicines, Division of Haematology, Cell and Gene Therapy, Germany (panelist)
• Ayal Hendel, Principal Investigator and Group Leader, Bar-Ilan University, Israel
• Blair Madison, Ph.D., Chief Scientific Officer, Gene Therapy at Poseida Therapeutics, United States
• Dana Carroll, Ph.D., Distinguished Professor Emeritus, University of Utah School of Medicine, United States
• Daniel Siegwart, Ph.D., Prof., University of Texas Southwestern Medical Center, United States
• Daniël Warmerdam, Ph.D., Assi. Prof., Amsterdam UMC, Netherlands (panelist)
• Dolça Rogers, Ph.D., ATMP topic lead, Pharmaceutical Quality Office, European Medicines Agency (EMA), Netherlands (panelist)
• Emma Wang, Ph.D., CTO, YolTech Therapeutics, China
• Eric B. Kmiec, Ph.D., Gene Editing Institue, Christianacare; CorriXR Therapeutics, Inc, United States
• Gerald Schwank, Prof., Ph.D., University of Zürich, Switzerland
• Guillermo Montoya, Prof., Research Director and Group Leader at the Protein Structure and Function program at CPR, University of Copenhagen, Denmark
• Jacob Corn, Prof., Ph.D., ETH Zürich, Switzerland
• Jakob Giehm Mikkelsen, Prof., Ph.D., Aarhus University, Denmark
• Jakob Nilsson, Prof., Ph.D., Danish Cancer Institute, Copenhagen, Denmark
• Julian Grünewald, Ass. Prof., MD, Ph.D., Technical University of Munich, Germany
• Karim Benabdel Lah El Khlanji, Senior Scientist at the GENyO Pfizer-University of Granada-Junta de Andalucia Center for Genomics and Oncological Research in Granada, Spain, GeneHumdi Action Chair
• Kiana Aran, Associate Professor of Bioengineering and Medicine, University of California San Diego, United States
• Marcello Maresca, Senior Director, Genome Engineering Team, AstraZeneca, Sweden
• Martin Pacesa, Ph.D., Laboratory of Protein Design and Immunoengineering at EPFL, Lausanne, Switzerland
• Matthew Porteus, Prof., MD, Ph.D., Stanford Medicine, United States
• Özcan Met, Ph.D., Associate Professor and Head of Cell Therapy Unit at the National Center for Cancer Immune Therapy (CCIT-DK) at Herlev University Hospital and DTU HealthTech, Denmark
• Raffaella Di Micco, Group Leader, Ph.D., SR-TIGET, Italy
• Rasmus O. Bak, Ass. Prof. and Group Leader, Aarhus University, Denmark
• Rob Wolthuis, Ph.D., Associate Prof., Amsterdam UMC, Netherlands
• Srinivasan Chandrasegaran, Ph.D., Professor Emeritus, Johns Hopkins School of Public Health, United States (panelist)
• Suk See De Ravin, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), United States
• Thorsten Stafforst, Ph.D., Professor at Interfaculty Institute of Biochemistry at the University of Tuebingen, Germany
• Tedd Elich, Ph.D., Chief Scientific Officer at Life Edit Therapeutics, United States
• Traver Hart, Ph.D., Associate Professor, MD Anderson Cancer Center, United States
• William H. Peranteau, MD, Surgeon and Professor, University of Pennsylvania/Children’s Hospital of Philadelphia, United States
• Xavier Duportet, Ph.D., CEO and Co-founder, Eligo Biosciences

Founders' Breakfast: April 8^th 2025, Copenhagen, Denmark (9:00 - 13:00 PM CET). Founders' Breakfast is an exclusive event for founders, investors and business development teams, working within the field of CRISPR Medicine. For more details and to reserve your seat, see here.

Confirmed speakers for Founders' Breakfast:

• Michael Krohn, Co-CEO, Akribion Therapeutics, Germany
• Jiawei Lee, Co-founder and Chief Business Officer, QUiCKR Bio, United States
• Jan Nelis, Project Lead and Co-Founder, Ariya Bio, Switzerland
• Michael Jackson, Venture Capitalist
• Monika Paule, CEO, Board Member and Co-Founder at CasZyme, Lithuania
• Rom Kshuk, CEO and Co-Founder at TaKenOti Bio, Israel
• Lene Gerlach, Venture Partner, Hadean Ventures, Denmark

Go to the Official CRISPRMED25 website to see the full updated list